AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month. Japan's second biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, the companies said in a statement. Astellas also said this month it had agreed to purchase Audentes Therapeutics Inc for about $3 billion to expand its push into genetic medicines.

NEW YORK, NY / ACCESSWIRE / January 3, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

WILMINGTON, Del., Dec. 23, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: LogMeIn, Inc. (NASDAQ GS: LOGM) regarding possible breaches of fiduciary.

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]

BALA CYNWYD, PA / ACCESSWIRE / December 30, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and ...

NEW YORK, NY / ACCESSWIRE / December 19, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

Moody's Japan K.K. has downgraded Astellas Pharma Inc.'s issuer rating to A2 from A1. At the same time, Moody's has changed the ratings outlook to negative from rating under review. This action concludes Moody's review for downgrade that was initiated on 6 December 2019, following Astellas' announcement it would acquire the outstanding stock of Audentes Therapeutics, Inc. Astellas has closed the USD 3 billion acquisition, financing it with debt and cash on hand.

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.

NEW YORK, NY / ACCESSWIRE / December 27, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

Guru invests in restructuring cancer drug developer Continue reading...

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Firm's largest buys of the 4th quarter Continue reading...

From Astellas' initial interest to the close of the deal took six months. But talks turned intense — and another suitor emerged — before the deal was struck Dec. 2.

NEW YORK, NY / ACCESSWIRE / December 18, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

BALA CYNWYD, PA / ACCESSWIRE / January 2, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and ...

NEW YORK, Dec. 21, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Audentes Therapeutics, Inc. (NASDAQ: BOLD).

BALA CYNWYD, PA / ACCESSWIRE / December 17, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and ...

Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

NEW YORK, NY / ACCESSWIRE / December 31, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...